Yahoo · Nov 12, 2026
GMRS vs. CRL: Which Stock Should Value Investors Buy Now?
GMRS vs. CRL: Which Stock Is the Better Value Option?

NYSE · CRL
Healthcare · Medical - Diagnostics & Research
$327.93
Down-$5.32 (-1.60%)
Updated Nov 20, 2026, 2:28 AM
SID Score
6.5/10
Composite research score
Smart Money
54/100
Neutral
Price performance · CRL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
CRL closed at $327.93 after 21 trading sessions, down 3.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $337.20 | $343.57 | $326.53 | $327.93 | 495.1K |
| Nov 18, 2026 | $332.15 | $338.53 | $330.405 | $333.25 | 516.51K |
| Nov 17, 2026 | $333.26 | $341.385 | $331.255 | $332.16 | 697.55K |
| Nov 16, 2026 | $334.13 | $338.20 | $328.68 | $335.52 | 693.84K |
| Nov 13, 2026 | $342.18 | $342.58 | $333.04 | $337.97 | 838.32K |
| Nov 12, 2026 | $335.66 | $342.83 | $326.29 | $340.81 | 902.12K |
| Nov 11, 2026 | $347.38 | $356.00 | $342.25 | $342.69 | 836.56K |
| Nov 10, 2026 | $350.44 | $352.50 | $342.39 | $345.80 | 822.08K |
| Nov 9, 2026 | $343.44 | $358.765 | $342.00 | $353.34 | 943.31K |
| Nov 6, 2026 | $318.73 | $339.97 | $316.61 | $337.52 | 1.06M |
| Nov 5, 2026 | $330.14 | $330.75 | $311.68 | $313.02 | 1.66M |
| Nov 4, 2026 | $349.90 | $354.99 | $325.35 | $326.29 | 1.73M |
| Nov 3, 2026 | $339.88 | $356.35 | $338.55 | $351.87 | 1.6M |
| Nov 2, 2026 | $368.42 | $369.61 | $337.37 | $338.54 | 1.62M |
| Oct 30, 2026 | $372.99 | $374.56 | $351.98 | $359.41 | 1.5M |
| Oct 29, 2026 | $375.00 | $379.63 | $368.63 | $376.10 | 887.34K |
| Oct 28, 2026 | $360.01 | $378.23 | $360.01 | $373.98 | 1.3M |
| Oct 27, 2026 | $351.95 | $359.89 | $351.95 | $358.84 | 1.16M |
| Oct 26, 2026 | $347.59 | $357.77 | $345.89 | $357.27 | 1.18M |
| Oct 23, 2026 | $337.78 | $347.195 | $332.17 | $345.37 | 822.3K |
| Oct 22, 2026 | $341.43 | $351.21 | $337.78 | $339.66 | 2.66M |
The latest Smart Investors Daily articles mentioning CRL.
Company
Market Activity
Research & News
CRL research
Company profile and research snapshot.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2026 | Evercore ISI Group | Outperform | — |
| Nov 5, 2026 | UBS | Buy | — |
| Nov 5, 2026 | Barclays | Overweight | — |
| Nov 5, 2026 | RBC Capital | Outperform | — |
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 12, 2026
GMRS vs. CRL: Which Stock Is the Better Value Option?
Yahoo · Nov 12, 2026
WILMINGTON, Mass., November 12, 2026--Charles River has announced a series of strategic investments and operational enhancements across its global Microbial Solutions network.
Yahoo · Nov 10, 2026
Charles River Laboratories International Inc. (NYSE:CRL) on Monday agreed to acquire the bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations of Frontage Holdings Corporation in Exton, Pennsylvania, for approximately $470 million in cash. The transaction also includes up to $75 million in performance-based earnout payments, positioning Charles River to capture expanding biopharmaceutical demand. Expanding Clinical Bioanalysis Capabilities And Balancing Laboratory Portfolio The
Yahoo · Nov 10, 2026
The transaction includes two testing sites in Exton, employing roughly 340 staff, and a CLIA-certified central laboratory.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CRL.